BPC-157Dosage, Side Effects & Legal Status
A synthetic fragment modeled on a peptide found in human gastric juice. Animal studies going back to the 1990s report accelerated healing of tendon, ligament, muscle, and gut tissue. Human data is limited to one small IRB-approved safety pilot and a handful of case reports, not the randomized trials that would normally back a dosing recommendation.
Reviewed by the PepGuard team · Last reviewed Jul 28, 2026
Pentadecapeptide (15 amino acids) · also sold as Body Protection Compound-157, Pentadecapeptide BPC 157
Photo: Abdulai Sayni / UnsplashWhat the literature and self-reports actually say.
| What's cited | Range |
|---|---|
| Commonly cited daily range | 250-500 mcg, once or twice daily |
| Commonly cited upper range | up to 1,000 mcg/day in some non-clinical protocols |
| Commonly cited weight-based range | ~2-4 mcg per kg of bodyweight per day, cited as an alternative to a flat dose in some protocols |
| Typical cited cycle length | 4-6 weeks, often followed by a break |
| Human safety pilot (IV, n=2) | up to 20 mg single infusion, no adverse events reported |
There is no FDA-approved or clinically validated human dose. The ranges below reflect what's most frequently cited across non-clinical, anecdotal, and vendor-reported protocols, not a recommendation from PepGuard or a clinician. The one published human safety pilot used intravenous dosing under IRB supervision, which is not comparable to self-administered subcutaneous use. The bands below double as a quick-reference dosage chart; the calculator further down this page converts any of them into an exact draw volume for your specific vial size.
Signal strength, not just a list.
How often each effect shows up in the available sources, and how solid that evidence actually is.
| Signal | Frequency | Context |
|---|---|---|
| Injection site reaction (redness, mild pain) | commonly reported | Consistent with subcutaneous injection generally, not specific to BPC-157's mechanism. |
| Nausea or dizziness | occasionally reported | Self-reported in anecdotal sources; not measured in a controlled human trial. |
| Fatigue or headache | occasionally reported | Same caveat: anecdotal, not from a controlled study. |
| Cardiovascular, liver, kidney, or thyroid markers | unknown / not studied | The one published human pilot (IV, n=2) found no measurable changes on these markers, but a 2-person pilot cannot establish population-level safety. |
| Long-term / cumulative effects | unknown / not studied | No published human trial has run long enough or enrolled enough people to answer this. |
Not FDA-approved. Unapproved research compound.
BPC-157 has never been approved by the FDA for any use in humans. It has moved in and out of the FDA's 503A bulk drug substance "Category 2" list (substances compounding pharmacies are barred from using over safety concerns) more than once as the agency's Pharmacy Compounding Advisory Committee has revisited it. That back-and-forth is the point: legal status here isn't settled, it's a moving target, which is exactly why checking current status before buying beats trusting a vendor's claim from six months ago.
Every claim above, traced back.
Primary studies, reviews, regulatory pages, and trial registries. Click through and check them yourself.
BPC-157 questions, answered.
No. It has never been approved by the FDA for any human use. It's sold by research chemical vendors as "not for human consumption," and its status on the FDA's compounding bulk-substance list has changed more than once as the agency's advisory committee has reviewed it.
Nobody can say for certain yet. The evidence for tissue healing comes almost entirely from animal studies. The only published human data is a small IRB-approved safety pilot (2 people, intravenous dosing) that found no adverse effects, which is not enough to establish safety for the general population or for self-administered subcutaneous use.
Non-clinical and anecdotal sources most often cite 250-500 mcg per day, typically injected near the site of injury for 4-6 weeks. This is not a clinically validated dose and not a recommendation, it's what shows up most often in the self-reported and vendor literature.
It's sold legally in the US as a "research use only" chemical, not as a supplement or drug for human use. Whether compounding pharmacies can legally formulate it into a prescription depends on its current FDA bulk-substance category, which has changed direction more than once. Check current status before assuming last year's answer still holds.
Non-clinical sources most often describe BPC-157 dosing as a flat 250-500 mcg per day rather than scaled to body weight, though some protocols cite roughly 2-4 mcg per kg as an alternative. Neither is a clinically validated method. Use the calculator on this page to convert whichever number you're working from into an exact draw volume for your vial size and concentration, it does the arithmetic, not the safety judgment.
Keep researching.
This is a preview of the BPC-157 report.
Create your account to check any peptide against the full research base.